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Objective: The rates of obesity and cigarette smoking are much higher in patients with
schizophrenia compared to the general population. This study was to examine whether
naltrexone and bupropion combination treatment can help weight loss and smoking
cessation in patients with schizophrenia.
Methods: Obese male schizophrenia patients with current cigarette smoking were
randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day)
combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study,
and 21 patients completed the study (11 in the treatment group, and 10 in the placebo
group). Body weight, body mass index (BMI), fasting lipids, smoking urge, expired carbon
monoxide (CO) level and cigarettes smoked per week were measured at baseline and
week 24.
Results: There was no significant difference between two groups in changes in weight,
BMI, fasting lipids, or cigarette smoking measures (p’s > 0.05)
Conclusion: Naltrexone and bupropion combination treatment didn’t show weight loss
or smoking cessation effect in patients with schizophrenia in this pilot study.Implications
for future studies were discussed.
ClinicalTrials.gov identifier: NCT02736474.
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INTRODUCTION
Schizophrenia is a devastating neuropsychiatric disease with a prevalence of 1% worldwide. The
rates of obesity are two times higher, and the rates of cigarette smoking are three to five times higher
in this patient population compared to the general population, (Marder et al., 2004; Morisano et al.,
2009). In a recent study of 896 Chinese patients with schizophrenia, 54% of them were found to be
overweight or obese (Guo et al., 2013). The high rate of cigarette smoking was consistently reported
in patients with schizophrenia across different cultures and countries (De Leon and Diaz, 2005).
The prevalence of cigarette smoking in male schizophrenia patients in China is in the range of
54–79% but the prevalence in female schizophrenia patients is remarkably lower at 4–7% (Hou
et al., 2011; Zhang et al., 2012). Notably, a common adverse effect of smoking cessation is weight
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gain (Yang et al., 2013). The average weight gain 6 months
after the quit date is between 2.3 and 4.5 kg (Farley et al.,
2009), which at least partially contributes to the difficulty in
quitting smoking, especially in those who are already obese.
Both obesity and cigarette smoking are significant risk factors
for cardiovascular disease and premature death (Hruby et al.,
2016; Cather et al., 2017). The mortality rate of schizophrenia
patients is approximately twice that of the general population
(Brown et al., 2000; Osby et al., 2000). Given the medical and
economic burden of obesity and cigarette smoking in this patient
population, establishing effective treatments targeting these two
problems would have important public health implication.
Bupropion is an approved medication for depression and
smoking cessation treatment. Bupropion can enhance subcortical
dopamine and norepinephrine effects and mitigate the effects
of nicotine-evoked dopamine transmission, therefore reduce
nicotine reward and withdrawal experiences (Mansvelder et al.,
2009). Studies have shown that bupropion is associated with a
reduction in smoking related cue-induced activation of limbic
and prefrontal brain regions (Culbertson et al., 2011). Clinically,
bupropion is commonly used in individuals with schizophrenia
for comorbid depression and/or smoking cessation. Recent
studies have demonstrated that bupropion increases the rates
of smoking abstinence and is well-tolerated in smokers with
schizophrenia (Tsoi et al., 2010).
The mechanisms underlying weight gain post cessation in
smokers are likely related to the results of heightened food
reward (Lerman et al., 2004) and increased intake of palatable
food with high sugar and fat contents (Hall et al., 1989). A
competitive opioid antagonist such as naltrexone might affect
opioidergic pathways and their connectivity to the midbrain
reward circuit involved in motivational and hedonic aspects of
feeding behaviors (Berridge et al., 2010). Recent studies suggested
that, of the pharmacological treatments studied thus far to reduce
weight gain after smoking cessation, the most promising results
have been obtained with naltrexone (King et al., 2012, 2013).
Research on central nervous system pathways that regulate
food intake and body weight has identified two key systems:
the hypothalamic melanocortin system, which integrates
input related to energy balance and produces anorexigenic
signaling, and the mesolimbic reward system, which modulates
reward value and goal-oriented behavior. Bupropion stimulates
hypothalamic proopiomelanocortin (POMC) neurons while
naltrexone can prevent inhibition of POMC neurons by blocking
the action of β-endorphin (Billes et al., 2014). The combined
treatment with sustained-release naltrexone (32 mg/day) and
bupropion (360 mg/day) (NB) has proven to be effective in
reducing body weight and improving cardiometabolic risks in
obese individuals with or without diabetes (Greenway et al.,
2010;Wadden et al., 2011; Hollander et al., 2013). The naltrexone
and bupropion combination was used in an open label 24-week
trial in overweight or obese nicotine-dependent subjects; the
results showed significantly decreased nicotine use and craving
without significant weight gain (Wilcox et al., 2010).
The combination of sustained-release naltrexone and
bupropion (NB) (Contrave, Orexigen, CA) has received FDA-
approval for weight loss in people who are overweight or obese
(Greenway et al., 2010; Wadden et al., 2011). The purpose
of the present 24-week, randomized, double blind, placebo
controlled pilot trial was to examine the feasibility, safety, and
initial benefit of using naltrexone and bupropion combination
in treating obesity and smoking cessation in patients with
schizophrenia.
METHODS
Study Participants
This study was approved by the ethics committee of Shanghai
Mental Health Center. Each participant provided written
informed consent. Male patients with schizophrenia were
recruited from the inpatient unit at Xuhui Mental Health Center
located in Shanghai, China. Each patient had 7 smoking breaks
throughout the day from 6:15 a.m. to 7:30 p.m. During these
15-min breaks, patients were allowed to smoke cigarettes freely.
The inclusion criteria were: (1) diagnosis of schizophrenia
by the International Classification of Diseases 10th Revision
(ICD-10); (2) age between 18 and 65 years old; (3) on stable
antipsychotic medication treatment for at least 1 month; (4) BMI
> 28 kg/m2 according to BMI criterion for obesity in the Chinese
population (Wu, 2006), or BMI > 27 kg/m2 in the presence of
dyslipidemia, or male with waist circumference over 90 cm; (5)
smoking at least 10 cigarettes daily for 1 year or longer; (6) desire
to lose weight and quit smoking.
The exclusion criteria were: (1) eating disorders; (2) currently
taking weight loss medications; (3) substance use (except caffeine
or nicotine); (4) clinically significant liver disease; (5) clinically
significant thyroid dysfunction; (6) history of epilepsy; (7) history
of unstable heart diseases or other unstable medical conditions.
A total number of 330 male patients with schizophrenia were
approached and screened between July 2016 and March 2017.
Among 28 patients who fit the inclusion and exclusion criteria,
22 of them were enrolled in the study. One patient in the placebo
group dropped out of the study after week-12 because of loss
of follow up after being discharged from the inpatient unit.
Therefore 21 patients (11 in the treatment group, 10 in the
control group) completed the 24-week trial and were included
in the final analysis.
Intervention
Following screening and confirmation that inclusion and
exclusion criteria were met, participants were randomized to
receive the combination treatment or placebo. Participants were
started with naltrexone 15mg and bupropion sustained release
150mg daily in the first 2 weeks. Then naltrexone was increased
to 15mg in the morning, 10mg in the afternoon, and bupropion
increased to 150mg twice per day as tolerated during the
remaining weeks of the study. Dosing targets were determined
based on the efficacy and side effects associated with various
dosing strategies reported in previous studies (Anderson et al.,
2002; Greenway et al., 2009), as well as the available supplies of
naltrexone and bupropion in China. Subjects were maintained
on the same antipsychotic medication at the same dosage when
clinically appropriate during the study.
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Outcome Measures
Medical and psychiatric histories were obtained, and physical
exam was performed for each participant. Urine drug screen
and 12-lead EKG were performed at baseline. The following
measures were completed at baseline and week 24: (1) height,
weight and waist circumference; (2) fasting lipids, fasting glucose,
HbA1c, and insulin; (3) breath CO level; (4) smoking craving
using the Visual Analogue Scale; (5) number of cigarettes smoked
in the past week; (6) the Positive and Negative Syndrome Scale
(PANSS), (7) the side effects questionnaire.
Laboratory Assays
Laboratory assays were performed by the Bio-Chemistry Lab
of Shanghai Mental Health Center. Fasting plasma glucose
was measured with a hexokinase reagent kit. Hemoglobin
A1C (HbA1c) was measured by high performance liquid
chromatography with an automated analyzer. Fasting total
plasma cholesterol and triglyceride levels were measured
enzymatically, and the HDL cholesterol fraction was measured
after precipitation of low-density lipoprotein (LDL) and very-
low-density lipoprotein (VLDL) with dextran sulfatemagnesium,
LDL levels were determined by the direct LDL reagents. Fasting
insulin was measured using immunochromatography.
Statistical Analysis
Data were analyzed using SPSS 24.0 (IBM Corp., Armonk,
NY). For baseline between-group comparisons, independent
student t-test was used for continuous variables and chi-
square test for categorical variables. Analysis of covariance
(ANCOVA) was used to examine the between-group differences
in changes of outcome measures from baseline to week 24
controlling for baseline values and other potential confounding
variables. A p < 0.05 (two-sided) was considered statistically
significant. Because this was designed as an exploratory pilot
study, adjustments were not made for multiple comparisons.
RESULTS
Baseline Characteristics
There were no significant differences between the two groups
on age, illness time duration, smoking time duration, breath
CO level, number of cigarettes smoked per week, smoking
craving, body weight, BMI, waist circumference, HbA1c, fasting
glucose, HDL, LDL and insulin, and the PANSS total and
subscale scores (p’s > 0.05). But the treatment group had
significantly higher levels of education and triglycerides than
the placebo group (p = 0.049 and p = 0.050, respectively)
(Table 1). In the treatment group, 5 patients were on clozapine,
7 on olanzapine, 8 on other antipsychotic agents (risperidone,
amisulpride, quetiapine, and chlorpromazine); in the placebo
group, 5 patients were on clozapine, 4 on olanzapine, 11 on other
antipsychotic agents (risperidone, amisulpride, paliperidone, and
chlorpromazine. There were no significant differences between
the two groups in the numbers of patients on clozapine or
olanzapine (p’s > 0.05).
TABLE 1 | Baseline demographic and general clinical characteristics.
Variable Treatment
group (N = 11)
(Mean + SD)
Placebo
group (N = 10)
(Mean + SD)
P-value
Age (years) 54.3 ± 5.7 56.2 ± 4.8 0.418
Education (years) 11.0 ± 2.8 8.1 ± 3.5 0.049*
Illness time duration (years) 29.8 ± 4.6 27.0 ± 8.8 0.400
Smoking time duration (years) 28.6 ± 7.8 32.4 ± 4.9 0.211
Breath CO Level (ppm) 27.1 ± 23.2 23.8 ± 9.0 0.679
Number of cigarettes smoked
per week
72.5 ± 5.7 77.0 ± 22.1 0.526
VAS smoking craving 6.3 ± 1.0 7.0 ± 1.4 0.202
Weight (kg) 74.7 ± 8.4 78.4 ± 10.6 0.380
BMI (kg/m2) 26.1 ± 2.9 27.6 ± 2.6 0.229
waist circumference (cm) 94.9 ± 4.5 98.8 ± 6.3 0.118
PANSS-Total 51.5 ± 17.4 55.9 ± 20.3 0.602
PANSS-Positive 10.0 ± 3.4 11.2 ± 6.1 0.579
PANSS-Negative 15.9 ± 5.4 19.9 ± 7.9 0.188
PANSS-General 24.3 ± 9.1 25.3 ± 11.1 0.819
Glucose (mmol/l) 5.5 ± 1.1 5.6 ± 2.3 0.903
HbA1c (%) 6.1 ± 0.6 6.4 ± 1.9 0.729
Triglyceride (mmol/l) 2.3 ± 1.1 1.4 ± 0.6 0.050*
HDL (mmol/l) 0.9 ± 0.2 0.8 ± 0.1 0.163
LDL (mmol/l) 2.8 ± 0.8 2.4 ± 0.9 0.234
Insulin (pmol/l) 106.8 ± 65.8 66.4 ± 20.2 0.095
VAS, visual analogue scale; BMI, body mass index; PANSS, the positive and negative
syndrome scale; HDL, high density lipoprotein; LDL, Low-density lipoprotein.
Outcome Measures After 24-Week
Treatment
After controlling for education level and baseline value, the
ANCOVA analysis showed no significant differences between the
two groups in week 24 changes for metabolic measures including
body weight, BMI, waist circumference, fasting glucose, HbA1c,
triglycerides, HDL, LDL, and insulin (p’s > 0.05) (Table 2). At
week 24, none of participants had successfully stopped smoking.
After controlling for education level and baseline value, the
ANCOVA analysis found no significant differences between the
two groups in week 24 changes for breath CO level, number of
cigarettes smoked per week, and smoking craving.
Adverse Reactions
During the 24-week study time period, five participants reported
dry mouth and1 participant reported mild abdominal discomfort
in the treatment group; 1 participant reported tachycardia in the
placebo group. There were no serious adverse events reported
during the study. No participants withdrew from the study
because of side effects.
DISCUSSION
Obesity and tobacco dependence are two major clinical
challenges in patients with schizophrenia. To date studies have
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TABLE 2 | Comparison of change values from baseline to week 24 on outcome
measures.
Outcome measure Change value (week 24min baseline)
Treatment group Placebo group p
N = 11 N = 10
(Mean + SD) (Mean + SD)
Body weight (kg) 0.2 ± 5.3 −0.9 ± 3.1 0.779
BMI (kg/m2) 0.0 ± 1.9 −0.3 ± 1.1 0.314
Glucose 0.5 ± 1.5 1.0 ± 1.6 0.264
HbA1c 0.05 ± 0.6 0.4 ± 1.1 0.385
Triglycerides −1.0 ± 0.9 −0.4 ± 0.6 0.591
HDL 0.0 ± 1.1 0.0 ± 0.1 0.657
LDL −0.4 ± 0.7 −0.2 ± 0.7 0.900
Insulin 3.5 ± 74.4 11.0 ± 35.3 0.262
Breath CO level (ppm) −5.3 ± 22.4 −7.2 ± 7.4 0.289
Cigarettes per week −6.2 ± 16.3 −6.3 ± 23.0 0.621
Craving scores −1.0 ± 2.9 −1.9 ± 3.1 0.481
Group comparisons were performed using ANCOVA controlling for baseline value and
education level.
generally focused on addressing one or the other but not
both. Identifying effective strategies to address both problems
simultaneously would have great clinical value and public
health implication. The current pilot study was designed
to test naltrexone and bupropion combination treatment to
address obesity and tobacco dependence together in individuals
with schizophrenia. To our knowledge, this was the first
study to target two difficult-to-treat conditions simultaneously
in this population. Our study suggests that naltrexone and
bupropion combination is well-tolerated in patients with
schizophrenia.
Our study failed to demonstrate benefit of naltrexone
and bupropion combination treatment for weight loss or
smoking cessation in patients with schizophrenia. Possible
reasons may include the small sample size, dosing of study
medication, peer pressure to engage in cigarette smoking in
the inpatient environment, and the absence of a psychosocial
intervention combined with the pharmacological intervention.
Another possibility is that the mechanisms related to obesity
and cigarette smoking in patients with schizophrenia may
not be responsive to naltrexone and bupropion combination
treatment. The high rates of tobacco dependence in individuals
with schizophrenia are believed to result from a range of
neurobiological vulnerability factors that likely act in concert
(Wing et al., 2012). Two overarching theories have been
proposed to explain the high rates of comorbid tobacco
addiction in schizophrenia. The self-medication hypothesis
proposes that people with schizophrenia smoke in an attempt
to improve psychiatric symptoms (Winterer, 2010). The
addiction vulnerability hypothesis proposes that common
abnormalities in the brain make patients with schizophrenia
more vulnerable to tobacco use (Wing et al., 2012). Previous
studies have demonstrated that treatment with first- and
second-generation antipsychotics contributes to weight gain
and obesity (Allison and Casey, 2001). In our study, ongoing
antipsychotic treatment may have counteracted the possible
weight loss effect of naltrexone and bupropion combination
treatment. Other possible limitations include: (1) Patients in
the study were able to smoke only during smoking breaks
rather than smoke freely; the smoking restriction might
have affected the smoking cessation outcome measure. (2)
Even though the desire to lose weight and quit smoking
was required for study participation, the level of motivation,
which is an important confounding factor, was not assessed
quantitatively in the present study. (3) The study included male
patients only due to the low prevalence of female smokers
in China; it is unclear whether or not there is a gender
difference in treatment response to naltrexone and bupropion
combination.
Obesity and tobacco dependence are two major clinical
challenges in patients with schizophrenia. To date studies
have singly focused on addressing one or the other. Novel
strategies to address both problems simultaneously would have
high clinical value and considerable public health implication.
Future studies with larger sample sizes and in combination with
psychosocial interventions, such as motivational interviewing
and/or nutritional counseling, are warranted to further explore
potential benefits of naltrexone and bupropion combination
treatment in treating obesity and cigarette smoking in patients
with schizophrenia.
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